36 Waldenstrom's Macroglobulinemia 1 1 0 3 3 271 http://clinicaltrials.dfhcc.harvard.edu/trials/271 Simvastatin in Waldenstrom's Macroglobulinemia This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months. Simvastatin is a drug approved by the FDA for lowering cholesterol. In test tube studies the study drug appears to have direct anti-cancer effect against WM tumor cells and mast cells. Recruiting 36 Waldenstrom's Macroglobulinemia http://clinicaltrials.dfhcc.harvard.edu/diagnoses/36-waldenstrom-s-macroglobulinemia Phase 2 1162 http://clinicaltrials.dfhcc.harvard.edu/trials/1162 LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia The purpose of this research study is to assess the response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstrom's Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma. Recruiting 36 Waldenstrom's Macroglobulinemia http://clinicaltrials.dfhcc.harvard.edu/diagnoses/36-waldenstrom-s-macroglobulinemia Phase 2 1213 http://clinicaltrials.dfhcc.harvard.edu/trials/1213 A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response. Recruiting 36 Waldenstrom's Macroglobulinemia http://clinicaltrials.dfhcc.harvard.edu/diagnoses/36-waldenstrom-s-macroglobulinemia